


82
43
cont
comprising reacting a compound of formula (VI)



wherein R³ is as defined above, with a trialkylorthoformate in the presence of an aqueous acid.

REMARKS

Claims 9, 18, and 22 have been amended for clarification. Support for the amendment is provided at page 10 of the specification and Example 8. Claims 9 and 18 – 22 are currently pending.

It is respectfully submitted that the present application is ready for examination on the merits. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Karen L. Prus, Ph.D.
Attorney for Applicant
Reg. No. 39,337

Date: *October 17, 2000*

Glaxo Wellcome Inc.
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709
Telephone: (919) 483-2192 Fax: (919) 483-7988